Literature DB >> 31361604

Crystal deposition triggers tubule dilation that accelerates cystogenesis in polycystic kidney disease.

Jacob A Torres1, Mina Rezaei1, Caroline Broderick1, Louis Lin1, Xiaofang Wang2, Bernd Hoppe3, Benjamin D Cowley4, Vincenzo Savica5, Vicente E Torres2, Saeed Khan6, Ross P Holmes7, Michal Mrug8,9, Thomas Weimbs1.   

Abstract

The rate of disease progression in autosomal-dominant (AD) polycystic kidney disease (PKD) exhibits high intra-familial variability suggesting that environmental factors may play a role. We hypothesized that a prevalent form of renal insult may accelerate cystic progression and investigated tubular crystal deposition. We report that calcium oxalate (CaOx) crystal deposition led to rapid tubule dilation, activation of PKD-associated signaling pathways, and hypertrophy in tubule segments along the affected nephrons. Blocking mTOR signaling blunted this response and inhibited efficient excretion of lodged crystals. This mechanism of "flushing out" crystals by purposefully dilating renal tubules has not previously been recognized. Challenging PKD rat models with CaOx crystal deposition, or inducing calcium phosphate deposition by increasing dietary phosphorous intake, led to increased cystogenesis and disease progression. In a cohort of ADPKD patients, lower levels of urinary excretion of citrate, an endogenous inhibitor of calcium crystal formation, correlated with increased disease severity. These results suggest that PKD progression may be accelerated by commonly occurring renal crystal deposition which could be therapeutically controlled by relatively simple measures.

Entities:  

Keywords:  Fibrosis; Genetic diseases; Nephrology

Year:  2019        PMID: 31361604      PMCID: PMC6763267          DOI: 10.1172/JCI128503

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  83 in total

Review 1.  mTOR signaling in growth control and disease.

Authors:  Mathieu Laplante; David M Sabatini
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

Review 2.  Impact of dietary habits on stone incidence.

Authors:  Roswitha Siener
Journal:  Urol Res       Date:  2006-01-11

3.  Are Cyst-Associated Macrophages in Polycystic Kidney Disease the Equivalent to TAMs in Cancer?

Authors:  Thomas Weimbs
Journal:  J Am Soc Nephrol       Date:  2018-09-12       Impact factor: 10.121

Review 4.  mTOR in aging, metabolism, and cancer.

Authors:  Marion Cornu; Verena Albert; Michael N Hall
Journal:  Curr Opin Genet Dev       Date:  2013-01-11       Impact factor: 5.578

5.  The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein.

Authors:  Christopher J Ward; Marie C Hogan; Sandro Rossetti; Denise Walker; Tam Sneddon; Xiaofang Wang; Vicky Kubly; Julie M Cunningham; Robert Bacallao; Masahiko Ishibashi; Dawn S Milliner; Vicente E Torres; Peter C Harris
Journal:  Nat Genet       Date:  2002-02-04       Impact factor: 38.330

Review 6.  Crystalluria: a neglected aspect of urinary sediment analysis.

Authors:  G B Fogazzi
Journal:  Nephrol Dial Transplant       Date:  1996-02       Impact factor: 5.992

Review 7.  Oxalate, inflammasome, and progression of kidney disease.

Authors:  Theresa Ermer; Kai-Uwe Eckardt; Peter S Aronson; Felix Knauf
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-07       Impact factor: 2.894

8.  The macrophage phenotype and inflammasome component NLRP3 contributes to nephrocalcinosis-related chronic kidney disease independent from IL-1-mediated tissue injury.

Authors:  Hans-Joachim Anders; Beatriz Suarez-Alvarez; Melissa Grigorescu; Orestes Foresto-Neto; Stefanie Steiger; Jyaysi Desai; Julian A Marschner; Mohsen Honarpisheh; Chongxu Shi; Jutta Jordan; Lisa Müller; Nicolai Burzlaff; Tobias Bäuerle; Shrikant R Mulay
Journal:  Kidney Int       Date:  2017-12-12       Impact factor: 10.612

9.  In female rats, ethylene glycol treatment elevates protein expression of hepatic and renal oxalate transporter sat-1 (Slc26a1) without inducing hyperoxaluria.

Authors:  Davorka Breljak; Hrvoje Brzica; Ivana Vrhovac; Vedran Micek; Dean Karaica; Marija Ljubojević; Ankica Sekovanić; Jasna Jurasović; Dubravka Rašić; Maja Peraica; Mila Lovrić; Nina Schnedler; Maja Henjakovic; Waja Wegner; Gerhard Burckhardt; Birgitta C Burckhardt; Ivan Sabolić
Journal:  Croat Med J       Date:  2015-10       Impact factor: 1.351

10.  Cytotoxicity of crystals involves RIPK3-MLKL-mediated necroptosis.

Authors:  Shrikant R Mulay; Jyaysi Desai; Santhosh V Kumar; Jonathan N Eberhard; Dana Thomasova; Simone Romoli; Melissa Grigorescu; Onkar P Kulkarni; Bastian Popper; Volker Vielhauer; Gabriele Zuchtriegel; Christoph Reichel; Jan Hinrich Bräsen; Paola Romagnani; Rostyslav Bilyy; Luis E Munoz; Martin Herrmann; Helen Liapis; Stefan Krautwald; Andreas Linkermann; Hans-Joachim Anders
Journal:  Nat Commun       Date:  2016-01-28       Impact factor: 14.919

View more
  18 in total

Review 1.  STAT signaling in polycystic kidney disease.

Authors:  Sebastian Strubl; Jacob A Torres; Alison K Spindt; Hannah Pellegrini; Max C Liebau; Thomas Weimbs
Journal:  Cell Signal       Date:  2020-04-20       Impact factor: 4.315

2.  ADPKD, Tolvaptan, and Nephrolithiasis Risk.

Authors:  Ewout J Hoorn; Robert Zietse
Journal:  Clin J Am Soc Nephrol       Date:  2020-06-11       Impact factor: 8.237

3.  Ketosis Ameliorates Renal Cyst Growth in Polycystic Kidney Disease.

Authors:  Jacob A Torres; Samantha L Kruger; Caroline Broderick; Tselmeg Amarlkhagva; Shagun Agrawal; John R Dodam; Michal Mrug; Leslie A Lyons; Thomas Weimbs
Journal:  Cell Metab       Date:  2019-10-17       Impact factor: 27.287

4.  Inhaled silica nanoparticles cause chronic kidney disease in rats.

Authors:  Fumihiko Sasai; Keegan L Rogers; David J Orlicky; Arthur Stem; Joshua Schaeffer; Gabriela Garcia; Jacob Fox; Matthew S Ray; Jaime Butler-Dawson; Marvin Gonzalez-Quiroz; Ricardo Leiva; Gangadhar Taduri; Sirirat Anutrakululchai; Vidhya Venugopal; Magdalena Madero; Jason Glaser; Julia Wijkstrom; Annika Wernerson; Jared M Brown; Richard J Johnson; Carlos A Roncal-Jimenez
Journal:  Am J Physiol Renal Physiol       Date:  2022-05-30

5.  Ketogenic dietary interventions in autosomal dominant polycystic kidney disease-a retrospective case series study: first insights into feasibility, safety and effects.

Authors:  Sebastian Strubl; Simon Oehm; Jacob A Torres; Franziska Grundmann; Jazmine Haratani; Morgan Decker; Sabrina Vuong; Amrit Kaur Bhandal; Nils Methot; Rhianna Haynie-Cion; Franziska Meyer; Florian Siedek; Uwe Korst; Roman-Ulrich Müller; Thomas Weimbs
Journal:  Clin Kidney J       Date:  2021-09-13

Review 6.  Contribution of phosphate and FGF23 to CKD progression.

Authors:  Kyle P Jansson; Alan S L Yu; Jason R Stubbs
Journal:  Curr Opin Nephrol Hypertens       Date:  2022-03-11       Impact factor: 3.416

7.  Crystal deposition aids cystogenesis.

Authors:  Susan J Allison
Journal:  Nat Rev Nephrol       Date:  2019-12       Impact factor: 28.314

8.  Interferon Regulatory Factor-5 in Resident Macrophage Promotes Polycystic Kidney Disease.

Authors:  Kurt A Zimmerman; Jifeng Huang; Lan He; Dustin Z Revell; Zhang Li; Jung-Shan Hsu; Wayne R Fitzgibbon; E Starr Hazard; Gary Hardiman; Michal Mrug; P Darwin Bell; Bradley K Yoder; Takamitsu Saigusa
Journal:  Kidney360       Date:  2020-03-26

Review 9.  Insights into Autosomal Dominant Polycystic Kidney Disease from Genetic Studies.

Authors:  Matthew B Lanktree; Amirreza Haghighi; Ighli di Bari; Xuewen Song; York Pei
Journal:  Clin J Am Soc Nephrol       Date:  2020-07-20       Impact factor: 8.237

10.  High Prevalence of Kidney Cysts in Patients With CYP24A1 Deficiency.

Authors:  Christian Hanna; Theodora A Potretzke; Andrea G Cogal; Yaman G Mkhaimer; Peter J Tebben; Vicente E Torres; John C Lieske; Peter C Harris; David J Sas; Dawn S Milliner; Fouad T Chebib
Journal:  Kidney Int Rep       Date:  2021-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.